Our Story

Out of respect for our patient's privacy and her oncologist's preference, we have chosen not to use names in this account. The clinical details are real. The journey is ours.

In early 2024, my wife was diagnosed with high-grade serous ovarian carcinoma, a rare and aggressive form of cancer affecting the ovaries, abdomen, and pelvis. She began treatment immediately, and what followed was nothing short of remarkable. By June 2024, her CA-125 tumor marker, the primary blood test used to track ovarian cancer activity, had dropped from 746.9 all the way down to 10.7. That is nearly normal. She was in remission. We exhaled for the first time in months.

It didn't last. By mid-2025, her CA-125 had begun climbing again, rising to 45.6. A CT scan in October 2025 confirmed what we feared, the cancer had returned and was now showing new growth in her abdomen and new nodules in her lungs. Her oncologist at MD Anderson Cancer Center in Houston, a physician we will call Dr. H., determined that the cancer had become platinum-resistant, meaning the chemotherapy drugs that had worked before were no longer effective. She did not qualify for available clinical trials. We were at a crossroads.

Testing revealed that her tumor expressed HER2 at a level called IHC 2+, a protein marker that made her eligible for a newer targeted therapy called ENHERTU (trastuzumab deruxtecan). On October 30, 2025, she started her first cycle. We were hopeful. But after five cycles, the results were clear, ENHERTU was not controlling the disease. Dr. H. made the decision to change course.

Additional molecular testing had shown that her tumor also expressed a protein called folate receptor alpha (FRα) at a high level, which made her eligible for a different targeted therapy called ELAHERE (mirvetuximab soravtansine). ELAHERE works by delivering chemotherapy directly to cancer cells that carry that FRα protein, leaving healthy cells largely untouched. She began ELAHERE treatment in 2026, continuing her care at MD Anderson under Dr. H.'s guidance.

As her husband and primary advocate through every one of these transitions, I threw myself into the research at each turn, clinical trials, drug mechanisms, integrative oncology protocols, and supplements. Because nearly 70% of cancer patients take supplements during treatment, and my wife wanted to do everything she could to support her body through every cycle. What I kept finding was a gap no supplement brand had filled. That gap became OncoCare.

OncoCare is the supplement brand cancer patients in active treatment actually need. Every formulation starts with the drug protocol, not the supplement aisle. We evaluate each ingredient against the target drug's mechanism, its CYP3A4 profile, its documented side effects, and the peer-reviewed literature specific to the target cancer type.

We launched with two indication-specific systems: OncoCare for Ovarian, built for patients on ELAHERE, and OncoCare for Breast, built for patients on ENHERTU (trastuzumab deruxtecan). The core formulation stack is 85% identical across both , which is itself a clinical insight. The differences are deliberate: Quercetin added for ENHERTU's black-box ILD risk, higher NAC for ENHERTU's GI burden, magnesium emphasis for ELAHERE's documented hypomagnesemia side effect.

What we put in matters. What we leave out matters just as much.